Usefulness of a Coronary Artery Disease Predictive Algorithm to Predict Global Risk for Cardiovascular Disease and Acute Coronary Syndrome.

[1]  M. Pencina,et al.  C-Reactive Protein and Reclassification of Cardiovascular Risk in the Framingham Heart Study , 2008, Circulation. Cardiovascular quality and outcomes.

[2]  Anders Larsson,et al.  Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. , 2008, The New England journal of medicine.

[3]  Francesca N. Delling,et al.  Heart Disease and Stroke Statistics—2018 Update: A Report From the American Heart Association , 2018, Circulation.

[4]  Solid-Timi Investigators.  Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial. , 2014 .

[5]  T. Assimes,et al.  Circulating chemokines accurately identify individuals with clinically significant atherosclerotic heart disease. , 2007, Physiological genomics.

[6]  M. Budoff,et al.  Intraindividual variability of C-reactive protein: the Multi-Ethnic Study of Atherosclerosis. , 2012, Atherosclerosis.

[7]  Richard Kones,et al.  Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey , 2011, Drug design, development and therapy.

[8]  V. Fuster,et al.  The use of high-sensitivity assays for C-reactive protein in clinical practice , 2008, Nature Clinical Practice Cardiovascular Medicine.

[9]  Michael J Blaha,et al.  High-sensitivity C-reactive protein and cardiovascular disease: a resolute belief or an elusive link? , 2013, Journal of the American College of Cardiology.

[10]  P. Libby,et al.  Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease , 2017, The New England journal of medicine.

[11]  John W McEvoy,et al.  An analysis of calibration and discrimination among multiple cardiovascular risk scores in a modern multiethnic cohort. , 2015, Annals of internal medicine.

[12]  A. Keech,et al.  Changes in Lipoprotein‐Associated Phospholipase A2 Activity Predict Coronary Events and Partly Account for the Treatment Effect of Pravastatin: Results From the Long‐term Intervention with Pravastatin in Ischemic Disease Study , 2013, Journal of the American Heart Association.

[13]  J. Danesh,et al.  Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies , 2010, The Lancet.

[14]  Lisa M. Schwartz,et al.  Distribution of C-reactive protein values in the United States. , 2005, The New England journal of medicine.

[15]  P. Ridker,et al.  Discordance of Low-Density Lipoprotein (LDL) Cholesterol With Alternative LDL-Related Measures and Future Coronary Events , 2014, Circulation.

[16]  R. Tibshirani,et al.  Coronary risk assessment among intermediate risk patients using a clinical and biomarker based algorithm developed and validated in two population cohorts , 2012, Current medical research and opinion.

[17]  David Couper,et al.  Race and Sex Differences in the Incidence and Prognostic Significance of Silent Myocardial Infarction in the Atherosclerosis Risk in Communities (ARIC) Study , 2016, Circulation.

[18]  V. Fuster,et al.  Coronary plaque disruption. , 1995, Circulation.

[19]  D. Levy,et al.  Multiple biomarkers for the prediction of first major cardiovascular events and death. , 2006, The New England journal of medicine.

[20]  B. Nordestgaard,et al.  Genetic determinants of LDL, lipoprotein(a), triglyceride-rich lipoproteins and HDL: concordance and discordance with cardiovascular disease risk , 2011, Current opinion in lipidology.

[21]  V. Fuster,et al.  Coronary artery calcification: pathophysiology, epidemiology, imaging methods, and clinical implications. A statement for health professionals from the American Heart Association. Writing Group. , 1996, Circulation.

[22]  S M Grundy,et al.  Improving coronary heart disease risk assessment in asymptomatic people: role of traditional risk factors and noninvasive cardiovascular tests. , 2001, Circulation.

[23]  N. Aggarwal,et al.  Lipoprotein(a) and Increased Cardiovascular Risk in Women , 2016, Clinical cardiology.

[24]  P. Pais,et al.  Darapladib for preventing ischemic events in stable coronary heart disease. , 2014, The New England journal of medicine.